Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging technique may predict heart events in amyloidosis patients

NCT ID NCT07154381

Recruiting now Knowledge-focused Sponsor: University Hospital, Essen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study is testing whether a special type of PET/MRI scan using a radioactive tracer called florbetaben can help predict major heart problems in people with cardiac amyloidosis. The researchers will follow 25 patients to see if certain scan results are linked to serious events like heart failure hospitalization or death. The goal is to find better ways to identify who is at highest risk, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Florbetaben (a radioactive tracer used in PET imaging)
What this could lead to
If successful, this study could identify imaging markers that help predict serious heart events in cardiac amyloidosis patients, potentially guiding earlier or more personalized care.
What could go wrong
This is a small, early observational study with only 25 participants. It is not testing a treatment, so it will not directly improve outcomes. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC AMYLOIDOSIS

Contacts and locations

Locations

  • Department of Nuclear medicine, University Hospital Essen

    RECRUITING

    Essen, North Rhine-Westphalia, 45147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.